Skip to content

Staar Surgical STAA Free cash flow

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$121M+26.0%
IAR
Integra LifeSciencesIART
-$5.05M+87.4%
ITG
Integer HoldingsITGR
$737K-87.8%
HRO
HarrowHROW
-$9.19M-147%
Glaukos logo
GlaukosGKOS

Other financials

Income statement

See full
Revenue$93.5M+120%
Gross profit$68.9M+146%
Operating income$8.0M+114%
Net income$5.2M+110%
EPS (diluted)$0.10+109%

Balance sheet

See full
Cash & equivalents$131.9M-23.8%
Total debt$37.3M+1.7%
Total equity$352.4M+0.7%
Total assets$451.1M-1.4%

Cash flow

See full
Operating cash flow-$21.7M-278%
CapEx$443.0K-69.8%

Valuation

See full
Market cap$1.44B+47.4%
Enterprise value$1.35B+61.6%
P/S+1.5×

Profitability

See full
Gross margin76.9%+2.9pp
Operating margin-9.1%-3.5pp
Net margin-7.2%-3.0pp
FCF margin-19.6%+55.9pp

Returns & leverage

See full
Return on equity-6%-2.4pp
Debt / equity0.1×0.0×
Current ratio5.1×+0.3×

Where this comes from

Calculated from Staar Surgical’s reported figures.

The official record: Staar Surgical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Staar Surgical's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Staar Surgical's free cash flow?
Staar Surgical (STAA) reported free cash flow of -$22.14M in Q1 2026.
How has Staar Surgical's free cash flow changed year-over-year?
Staar Surgical's free cash flow decreased by 207.4% year-over-year, from -$7.2M to -$22.14M.
What is the long-term trend for Staar Surgical's free cash flow?
Over 3 years (2021 to 2025), Staar Surgical's free cash flow has grown at a 11.3% compound annual growth rate (CAGR), from $30.32M to -$41.83M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.